Solvonis Therapeutics PLC to acquire Awakn

Solvonis Therapeutics PLC has agreed to acquire Awakn, a biopharmaceutical company based in Canada, in a strategic acquisition. The transaction was announced on 28 May 2025, although records indicate the deal was completed on the preceding day, 27 May 2025. Consideration for the acquisition was provided in the form of shares, though the specific value of the deal was not disclosed to the public. This transaction represents a significant expansion for the buyer within the biopharmaceutical sector, bringing the target company under new ownership.

The deal structure involved a straightforward exchange of equity, with no cash consideration reported in the available data. Both parties have confirmed that the transaction has been finalised, marking the end of the acquisition process. As the deal is already completed, no further regulatory approvals are pending for the transfer of ownership. The integration of Awakn into Solvonis Therapeutics PLC is now underway, concluding the acquisition phase.